Samumed

Samumed completes phase I chronic tendinopathy study

Monday, July 24, 2017

Samumed, a leader in musculoskeletal conditions, announced the successful completion of a phase I clinical trial in healthy subjects for its potential treatment of chronic tendinopathy, a degenerative and fibrotic condition caused by injuries or overuse and that has no FDA-approved drug treatments today. The study results supported the continuation of the program into future studies in tendinopathy patients. There were no serious adverse events related to the drug (as deemed by the investigators) and a maximum tolerated dose was not reached in any of the three treatment groups. A detailed analysis, including safety and pK results, will be presented at a future medical conference.

[Read More]